These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 18048389)

  • 21. Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteine.
    Orue A; Chavez V; Strasberg-Rieber M; Rieber M
    BMC Cancer; 2016 Nov; 16(1):902. PubMed ID: 27863474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain.
    Lambert JM; Gorzov P; Veprintsev DB; Söderqvist M; Segerbäck D; Bergman J; Fersht AR; Hainaut P; Wiman KG; Bykov VJ
    Cancer Cell; 2009 May; 15(5):376-88. PubMed ID: 19411067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion.
    Nahi H; Merup M; Lehmann S; Bengtzen S; Möllgård L; Selivanova G; Wiman KG; Paul C
    Br J Haematol; 2006 Jan; 132(2):230-6. PubMed ID: 16398657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors.
    Liang Y; Besch-Williford C; Benakanakere I; Thorpe PE; Hyder SM
    Breast Cancer Res Treat; 2011 Jan; 125(2):407-20. PubMed ID: 20349129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression proteomics to p53 mutation reactivation with PRIMA-1 in breast cancer cells.
    Lee K; Wang T; Paszczynski AJ; Daoud SS
    Biochem Biophys Res Commun; 2006 Oct; 349(3):1117-24. PubMed ID: 16970918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells.
    Rehman A; Chahal MS; Tang X; Bruce JE; Pommier Y; Daoud SS
    Breast Cancer Res; 2005; 7(5):R765-74. PubMed ID: 16168122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antitumor Effects of PRIMA-1 and PRIMA-1
    Menichini P; Monti P; Speciale A; Cutrona G; Matis S; Fais F; Taiana E; Neri A; Bomben R; Gentile M; Gattei V; Ferrarini M; Morabito F; Fronza G
    Cells; 2021 Jan; 10(1):. PubMed ID: 33430525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis.
    Bykov VJ; Zache N; Stridh H; Westman J; Bergman J; Selivanova G; Wiman KG
    Oncogene; 2005 May; 24(21):3484-91. PubMed ID: 15735745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53.
    Zache N; Lambert JM; Wiman KG; Bykov VJ
    Cell Oncol; 2008; 30(5):411-8. PubMed ID: 18791272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells.
    Rangel LP; Ferretti GDS; Costa CL; Andrade SMMV; Carvalho RS; Costa DCF; Silva JL
    J Biol Chem; 2019 Mar; 294(10):3670-3682. PubMed ID: 30602570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU.
    Li X; Yu J; Brock MV; Tao Q; Herman JG; Liang P; Guo M
    Oncotarget; 2015 May; 6(13):11547-60. PubMed ID: 25909168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological reactivation of mutant p53: from protein structure to the cancer patient.
    Wiman KG
    Oncogene; 2010 Jul; 29(30):4245-52. PubMed ID: 20498645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PRIMA-1 synergizes with adriamycin to induce cell death in non-small cell lung cancer cells.
    Magrini R; Russo D; Ottaggio L; Fronza G; Inga A; Menichini P
    J Cell Biochem; 2008 Aug; 104(6):2363-73. PubMed ID: 18442053
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mcl-1 as a potential therapeutic target for human hepatocelluar carcinoma.
    Yu Q; Liu ZY; Chen Q; Lin JS
    J Huazhong Univ Sci Technolog Med Sci; 2016 Aug; 36(4):494-500. PubMed ID: 27465322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
    Synnott NC; Murray A; McGowan PM; Kiely M; Kiely PA; O'Donovan N; O'Connor DP; Gallagher WM; Crown J; Duffy MJ
    Int J Cancer; 2017 Jan; 140(1):234-246. PubMed ID: 27615392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer.
    Farnebo M; Bykov VJ; Wiman KG
    Biochem Biophys Res Commun; 2010 May; 396(1):85-9. PubMed ID: 20494116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line.
    Chan KT; Lung ML
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):519-26. PubMed ID: 15004724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RBM38 plays a tumor-suppressor role via stabilizing the p53-mdm2 loop function in hepatocellular carcinoma.
    Ye J; Liang R; Bai T; Lin Y; Mai R; Wei M; Ye X; Li L; Wu F
    J Exp Clin Cancer Res; 2018 Sep; 37(1):212. PubMed ID: 30176896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of hepatitis-B-virus core promoter by p53: implications for carcinogenesis in hepatocytes.
    Uchida T; Takahashi K; Tatsuno K; Dhingra U; Eliason JF
    Int J Cancer; 1996 Sep; 67(6):892-7. PubMed ID: 8824564
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant adeno-associated virus expressing a p53-derived apoptotic peptide (37AA) inhibits HCC cells growth in vitro and in vivo.
    Zhang H; Wang Y; Bai Y; Shao Y; Bai J; Ma Z; Liu Q; Wu S
    Oncotarget; 2017 Mar; 8(10):16801-16810. PubMed ID: 28187431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.